HEAD & NECK CANCER

This study tests a new drug called RiMO-301 combined with targeted radiation and an immunotherapy drug (a PD-1 inhibitor) in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find a safe dose and see if the treatment shrinks…

This study tests a weekly combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab) in 32 people with metastatic head and neck cancer who cannot take the standard drug 5-fluorouracil. The goal is to see if this regimen shrinks tumors better than …

This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps control advanced head and neck cancer better than radiation alone. It is for patients who cannot take platinum-based chemotherapy. About 335 adults with stage III-IVB head and neck s…

This study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread and have a specific marker (FGFR1). The drug is an antibody given by IV every two weeks. The goal is to find a safe dose and see if it can slow tumor growth. About 58 adults with …

This study tests whether giving a mix of two drugs (nimotuzumab and toripalimab) plus chemotherapy before surgery can help eliminate tonsil cancer cells in people with advanced disease. About 10 adults with resectable tonsil cancer will receive the treatment and then have surgery…

This study tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. After surgery, patients receive radiation therapy combined with a targeted drug (nimotuzumab), followed by an immunotherapy drug (benmelsto…

This early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…

This study tests whether a special ultrasound with contrast dye can find the first lymph node where cancer might spread, instead of using the standard radioactive method. About 91 adults with melanoma, breast cancer, or head & neck cancer will take part. If it works, it could mak…

This early study is testing a new imaging agent called FL-261 to see if it can safely and accurately detect and stage several types of cancer, including lung, colorectal, and head & neck cancers. The agent targets a protein (c-MET) found on many cancer cells but not on most healt…

This study is testing whether a detailed PET-CT scan (called micro-PET-CT) can accurately show the edges of head and neck cancers during surgery. Ten adults with operable tumors will receive the scan, and the results will be compared to standard lab analysis of the removed tissue…

This early-stage study tests whether a precise ultrasound beam aimed at a pain center in the brain can safely reduce severe, opioid-resistant pain in people with head, neck, or brachial cancer. About 20 adults aged 18–85 will receive the one-time procedure. The goal is to see if …

This study examines tissue samples from people with laryngeal dysplasia, a precancerous condition of the throat, to find genetic and immune changes that may signal progression to cancer. By analyzing immune cells in the tissue, researchers hope to better predict which cases are l…

This study looks at how much head and neck cancer patients and dentists know about dental care during cancer treatment. About 132 people will fill out a questionnaire before and after reading simple, guideline-based information. The goal is to see if this information helps them m…

This study looks at whether a special PET scan taken 6 weeks after starting immunotherapy can predict how well the treatment will work later. It involves 25 adults with advanced head and neck cancer who are starting a drug called pembrolizumab. The goal is to see if early changes…